Oppenheimer's Rating of ACADIA Pharmaceuticals on 11/18/2026

On November 18, 2026, Oppenheimer updated its outlook on ACADIA Pharmaceuticals (NASDAQ:ACAD) with the action "Reiterated Rating", keeping a "Market Perform" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Oppenheimer Holdings, Inc.

DateCompanyAction
11/19/2026
Unusual Machines, Inc. stock logo
UMAC
Unusual Machines
Initiated Coverage
11/19/2026
SWMR
Swarmer
Initiated Coverage
11/19/2026
Redwire Corporation stock logo
RDW
Redwire
Initiated Coverage
11/19/2026
Planet Labs PBC stock logo
PL
Planet Labs PBC
Initiated Coverage
11/19/2026
HAWK
HawkEye 360
Initiated Coverage
11/18/2026
Deere & Company stock logo
DE
Deere & Company
Reiterated Rating
More Ratings From Oppenheimer Holdings, Inc.